While conventional targeted therapies on ER, PR, or HER2 have been applied for breast cancer patients with luminal A, luminal B, or HER2 subtypes, the treatment options for triple-negative breast cancer (TNBC) are still limited, resulting in poor prognosis [22,23]. This evidence concerns the gene ESR1 and breast carcinoma.